Journal
ACS MEDICINAL CHEMISTRY LETTERS
Volume 7, Issue 3, Pages 283-288Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsmedchemlett.5b00448
Keywords
GPCR; S1P1; S1P3; biased signaling
Categories
Ask authors/readers for more resources
Clinical validation of SIP receptor modulation therapy was achieved with the approval of fingolimod (Gilenya, 1) as the first oral therapy for relapsing remitting multiple sclerosis. However, 1 causes a dose-dependent reduction in the heart rate (bradycardia), which occurs within hours after first dose. We disclose the identification of clinical compound BMS-986104 (3d), a novel S1P(1) receptor modulator, which demonstrates ligand-biased signaling and differentiates from 1 in terms of cardiovascular and pulmonary safety based on preclinical pharmacology while showing equivalent efficacy in a T-cell transfer colitis model.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available